APG Asset Management N.V. Buys 59,984 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

APG Asset Management N.V. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 275.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 81,755 shares of the biopharmaceutical company’s stock after purchasing an additional 59,984 shares during the quarter. APG Asset Management N.V.’s holdings in Regeneron Pharmaceuticals were worth $56,240,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of REGN. Pamalican Asset Management Ltd acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $4,915,000. Intact Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $356,000. Principal Financial Group Inc. increased its stake in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Fagan Associates Inc. raised its holdings in Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock worth $9,205,000 after buying an additional 3,832 shares during the period. Finally, Golden State Equity Partners lifted its stake in Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 1,272 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on REGN shares. Bernstein Bank dropped their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Robert W. Baird cut their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. Finally, Truist Financial reduced their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Trading Down 2.8 %

Shares of Regeneron Pharmaceuticals stock opened at $556.81 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business has a fifty day simple moving average of $669.26 and a two-hundred day simple moving average of $766.90. Regeneron Pharmaceuticals, Inc. has a 1 year low of $546.36 and a 1 year high of $1,211.20. The company has a market capitalization of $60.87 billion, a price-to-earnings ratio of 14.55, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.86 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.